Highlights
- The FDA accepted the D-PLEX100 NDA on July 27, 2026 with no filing review issues and granted Priority Review, which sets a PDUFA goal date of November 28, 2026.
- PolyPid signed an exclusive U.S. and Canada commercialization Partnership with Azurity Pharmaceuticals, with USD 30 million secured in upfront and near-term milestones.
- The second quarter net loss was USD 7.8 million, or USD 0.35 per share, against USD 10.0 million, or USD 0.78.
- Management expects existing cash to fund operations into 2028 and Azurity to launch D-PLEX100 in the U.S. in early 2027.
PolyPid Ltd. (NASDAQ:PYPD) shares were trading near their 52-week high at USD 6.14 on November 6, 2026, up 8.29%. The company reported second quarter 2026 results in August, with the D-PLEX100 NDA accepted and a commercialization partnership signed with Azurity.
PolyPid is a clinical stage company that files annual reports on Form 20-F. Its lead product, D-PLEX100, is designed for the prevention of surgical site infection in patients undergoing abdominal colorectal surgery, and its Kynatrix technology supports additional pipeline opportunities. PolyPid has a market Capitalization of USD 124.71 million and no reported price to Earnings ratio. Its fiscal year ends December 31.
Regulatory Progress
PolyPid completed the NDA submission for D-PLEX100 in the second quarter. On July 27, 2026 the FDA formally accepted the NDA for filing ahead of the company's internal timeline and identified no filing review issues. The FDA granted Priority Review, which shortens the review period from 10 months to 6 months and sets the PDUFA goal date at November 28, 2026. The company is also engaged with the European Medicines Agency on a planned Marketing Authorization Application and is preparing for the FDA pre-approval inspection.
Azurity Partnership
PolyPid signed an exclusive commercialization partnership with Azurity Pharmaceuticals for the United States and Canada. It has secured USD 30 million in aggregate upfront and near-term milestones, made up of USD 15 million at signing and USD 15 million on FDA acceptance of the NDA. It is eligible for over USD 290 million in additional regulatory, launch and sales milestones, tiered royalties from the mid-teens to the mid-20s percentages, and a transfer price on every unit it manufactures and supplies. Azurity funds the label expansion program under the joint development agreement, and it plans a U.S. launch in early 2027.
Second Quarter Results
Research and development expenses were USD 6.1 million against USD 6.2 million and reflect NDA related activities and commercial readiness preparation. General and administrative expenses fell to USD 1.3 million from USD 2.5 million because noncash expenses for performance based Options fell after the positive Phase 3 SHIELD II topline results triggered vesting. Marketing and Business development expenses were USD 0.5 million against USD 0.7 million.
The net loss was USD 7.8 million, or USD 0.35 per share, against USD 10.0 million, or USD 0.78. The net loss for the first six months was USD 15.6 million against USD 18.2 million.
Balance Sheet
Cash and cash equivalents were USD 6.6 million at June 30, 2026, against USD 12.9 million of cash, cash equivalents and short term deposits at December 31, 2025. After quarter end PolyPid received USD 15 million from Azurity at signing and a further USD 15 million on FDA acceptance of the NDA. The only warrants outstanding are those issued in June 2025, with USD 7.3 million remaining and an expiration date in June 2027.
Outlook
Management expects its cash resources to fund operations into 2028. The next milestone is the FDA decision on the D-PLEX100 NDA by the PDUFA goal date of November 28, 2026, followed by the planned U.S. launch by Azurity in early 2027.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...